New Orally Available Compound Seen to Increase Activity of Human Parathyroid Hormone Receptor 1
A new, small, orally available compound has the potential to regulate abnormal calcium levels often seen in patients with hypoparathyroidism, according to preclinical research. The study, “Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small-Molecule for Treatment of Hypoparathyroidism,” was published…